Testing a new kidney disease treatment for children on dialysis

Plain-English translation of NCT03969329 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing a medication called to see if it works and is safe for children and adolescents (ages 2–17) who have kidney disease and are receiving dialysis treatment. The medication is designed to help control a condition where the parathyroid glands become overactive due to kidney disease. Researchers will measure how well the medication works, how the body processes it, and what side effects occur.

Children with advanced kidney disease often develop overactive parathyroid glands, which can cause bone and mineral problems. This medication has shown promise in adults, but doctors need to test it carefully in children to make sure it's safe and effective at the right doses for younger patients.

Do you qualify?

You likely qualify if…

you are between 2 and 17 years old at the time you enroll
you have been diagnosed with chronic kidney disease and secondary hyperparathyroidism
you are currently receiving dialysis treatment at least three times per week and have been for at least one month
your parathyroid hormone levels are high (mean of 2 tests greater than 300 pg/mL) when checked during the screening period
your parent or legal guardian can provide informed consent, and you can provide written agreement to participate based on your age

You likely don't qualify if…

you have a personal or family history of long QT syndrome or certain heart rhythm problems
you are scheduled to have parathyroid gland surgery or a kidney transplant during the trial
you have had parathyroid gland surgery within the past 6 months
you have been diagnosed with cancer (other than certain skin cancers) in the past 5 years or currently have cancer
you are taking other medications known to affect heart rhythm (such as certain anti-nausea drugs or antibiotics)

What participation looks like

You would receive the new medication as an injection in addition to your regular dialysis treatment and standard care. The study will gradually adjust your dose to find the amount that works best for you. You will have regular blood tests and clinic visits so doctors can check how well the medication is working, measure your hormone levels, and monitor for any side effects. The study involves careful tracking of your response to make sure the medication is both safe and effective.

AI-generated summary from trial data · Jun 18, 2026 · Not medical advice

Trial locations(23 sites)

Belgium

Universitair Ziekenhuis Gent, Ghent

Czechia

Fakultni nemocnice v Motole, Prague

France

Hospices Civils de Lyon Hopital Femme Mere Enfant, Bron

Hopital Armand Trousseau, Paris

Germany

Kindernierenzentrum Bonn, Bonn